Six-month results from the COMP006 Phase 3 trial show COMP360 delivers rapid and durable benefits in highly chronic treatment-resistant depression, with 39% of patients achieving significant improvement and nearly 30% of responders reaching remission after retreatment. Safety profile remains favorable, and regulatory submission is progressing.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.